Adagene Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ADAG research report →
Range $7 – $10
Price Chart
About the company
Adagene Inc. functions as a clinical-stage biopharmaceutical organization, primarily concentrating on the identification, evolution, and fabrication of monoclonal antibody-based therapeutics engineered to combat various types of cancer. The company's developmental pipeline encompasses several investigational assets currently undergoing human trials.
- CEO
- Peter Luo
- IPO
- 2021
- Employees
- 128
- HQ
- Suzhou, JS, CN
Get TickerSpark's AI analysis on ADAG
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $66.26M
- P/E
- -3.86
- PEG
- -0.04
- P/S
- 7.35
- P/B
- 0.78
- EV/EBITDA
- 2.44
- Div Yield
- 0.00%
- Gross Margin
- 94.22%
- Op Margin
- -240.31%
- Net Margin
- -220.66%
- ROE
- -29.09%
- ROIC
- -19.62%
Latest fiscal year · YoY change
- Revenue
- $7.67M+7332.8%
- Gross Profit
- $7.67M+1032.0%
- Op Income
- $-21,438,295
- Net Income
- $-17,609,413+47.3%
- EPS
- $-0.46+51.3%
- OCF Growth
- +47.3%
- FCF Growth
- +47.3%
- 52W High
- $4.85
- 52W Low
- $1.27
- 50D MA
- $2.58
- 200D MA
- $3.39
- Beta
- 0.54
- RSI (14)
- 39
- Avg Volume
- 328.35K
No earnings-call transcripts are available for ADAG yet.
- Free Float
- 71.7%
- Shares Outstanding
- 37.65M
- Float Shares
- 26.99M
of shares held by institutions
36 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Janus Henderson Group Ltd. | 6.67M | ▲ 6.67M |
| Jupiter Topco LLC | 6.67M | ▲ 6.67M |
| Deerfield Management Company, L.P. | 2.67M | 0 |
| Ameriprise Financial Inc | 1.72M | ▲ 5 |
| Squadron Capital Management LLC | 1.62M | ▲ 366.62K |
| Hsg Holding Ltd | 1.34M | 0 |
| Flputnam Investment Management Co | 682.27K | ▲ 682.27K |
| Marshall Wace, Llp | 452.31K | ▲ 383.21K |
| Birchview Capital, LP | 430.00K | ▲ 190.00K |
| Siren, L.L.C. | 421.66K | ▼ 2.25M |
| Dauntless Investment Group, LLC | 282.75K | ▼ 254.48K |
| Moneta Group Investment Advisors LLC | 200.00K | 0 |
Held by 3 ETFs
Biggest fund positions in ADAG by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 30, 26 | GU CHUNFANG | other | 0 |
| Sep 23, 26 | Tam Man Kin | buy | 2,000 |
| Sep 16, 26 | Luo Peter | buy | 20,290 |
| Aug 14, 26 | DO CUONG V | buy | 2,000 |
| Aug 13, 26 | Zhu Li | other | 20,000 |
| Aug 13, 26 | Cheung Andy Yiu Leung | other | 20,000 |
| Aug 13, 26 | DO CUONG V | other | 20,000 |
| Aug 13, 26 | Grawunder Ulf | other | 20,000 |
| Aug 5, 26 | Luo Peter | buy | 279 |
| Aug 4, 26 | Luo Peter | buy | 22,966 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ADAG coverage
Recent articles, reports, and earnings notes.
No research on ADAG yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ADAG report →Adagene Announces First Patient Dosed in Phase 1 Study of ADG138, a Novel HER2xCD3 Double-Masked Bispecific T-Cell Engager
globenewswire.com · Nov 19
City of Hope and Adagene Open Clinical Trial to Test New Therapy for Patients with Hard-to-Treat Colorectal Cancer
businesswire.com · Nov 17
Adagene and City of Hope Open Clinical Trial to Test New Therapy for Patients with Hard-to-Treat Colorectal Cancer
globenewswire.com · Nov 17
Adagene Announces Completion of Enrollment in Randomized Dose Optimization Phase 2 Trial of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorectal Cancer
globenewswire.com · Nov 9
Adagene Announces Dosing of First Patient in Phase 1 Study of Muzastotug in Combination with Incyte's INCA33890 in Patients with Microsatellite Stable Colorectal Cancer
globenewswire.com · Oct 28
Adagene to Participate in the Guggenheim Securities 3rd Annual Healthcare Innovation Conference
globenewswire.com · Oct 27
Adagene Eyes Phase II Data for Masked CTLA-4 Therapy in MSS Colorectal Cancer
marketbeat.com · Oct 25
Adagene (NASDAQ:ADAG) Stock Rating Reaffirmed as “Buy” by HC Wainwright
defenseworld.net · Oct 19
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.